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Objective—Emerging evidence suggests that human blood contains bone marrow (BM)-derived endothelial progenitor
cells that contribute to postnatal neovascularization. Clinical trials demonstrated that administration of BM-cells can
enhance neovascularization. Most studies, however, used crude cell populations. Identifying the role of different cell
populations is important for developing improved cellular therapies.
Methods and Results—Effects of the hematopoietic stem cell–containing CD34 cell population on migration,
proliferation, differentiation, stimulation of, and participation in capillary-like tubule formation were assessed in an in
vitro 3-dimensional matrix model using human microvascular endothelial cells. During movement over the endothelial
monolayer, CD34 cells remained stuck at sites of capillary tube formation and time- and dose-dependently formed cell
clusters. Immunohistochemistry confirmed homing and proliferation of CD34 cells in and around capillary sprouts.
CD34 cells were transduced with the LNGFR marker gene to allow tracing. LNGFR gene–transduced CD34 cells
integrated in the tubular structures and stained positive for CD31 and UEA-1. CD34 cells alone stimulated
neovascularization by 17%. Coculture with CD34 cells led to 68% enhancement of neovascularization, whereas CD34
cells displayed a variable response by themselves. Cell–cell contact between CD34 and CD34 cells facilitated
endothelial differentiation of CD34 cells.
Conclusions—Our data suggest that administration of CD34-enriched cell populations may significantly improve
neovascularization and point at an important supportive role for (endogenous or exogenous) CD34 cells. (Arterioscler
Thromb Vasc Biol. 2005;25:1843-1850.)
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The formation of new capillaries plays a critical role inphysiological and pathological processes such as wound
healing, ischemia, and tumor growth. It has long been thought
that postnatal neovascularization occurred exclusively by migra-
tion and proliferation of preexisting endothelial cells (angiogen-
esis). Increasing evidence indicates that bone marrow (BM)-
derived circulating endothelial progenitor cells (EPCs) are also
involved in postnatal new vessel formation,1 a process that,
reminiscent of embryonic vessel formation, is termed adult
vasculogenesis.2 The concept of “therapeutic vasculogenesis,”
administration of adult progenitor cells or progenitor-containing
cell populations to stimulate neovascularization, and the poten-
tial of progenitor cells to serve as new vehicles for gene therapy
have received a lot of scientific attention. Several small clinical
trials aimed at therapeutic vasculogenesis by autologous trans-
plantation of BM cells have been performed and improved
clinical outcomes in patients with severe chronic limb ischemia
or myocardial ischemia have been reported.3–6
An important question concerning therapeutic vasculogen-
esis is, which cell population should be administered? Thus
far, most clinical studies have used nonselected BM mono-
nuclear cells; however, administration of such crude cell
populations may have unwanted side effects. Recent data
suggest that beside EPCs, BM contains other progenitor cells
that may contribute to atherosclerosis,7 whereas hematopoi-
etic cells were reported to have the capacity to produce
profibrotic and angiogenic factors.8,9 Better characterization
of the BM cell subpopulation that can generate EPCs is of
critical importance to development of safer and better-
targeted cellular therapies.
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Several studies have suggested that in human postnatal life,
analogous to the existence of the embryonic hemangioblast,10
the CD34 hematopoietic stem cell population contains cells
that can give rise to EPCs and endothelial cells.1,11,12 This
would suggest the potential use of CD34-enriched cell
populations in therapeutic vasculogenesis. Various authors
reported that administration of human leukocytes enriched for
CD34 cells effectively enhanced neovascularization in ani-
mal models.1,13,14 However, it has been argued that, because
of lack of purity of the CD34-enriched cell populations and
use of vital dye labeling of CD34 cells with possible dye
transfer among cells, definitive proof that CD34 cells are
angioblasts is lacking.15 Several investigators pointed at a
more important role for the CD34CD14 monocytic cell
population.15–19 Interestingly, recent reports suggest that the
majority of blood-derived cultured acetylated low-density
lipoprotein (LDL) and Ulex europeus double-positive cells,
which are commonly referred to as EPCs, may be derived
from monocytes/macrophages.20 We previously demon-
strated that a minor but significant subset (9%) of cultured
EPC originates from the CD34 mononuclear cell popula-
tion.21 It has been suggested that EPCs derived from the
monocyte/macrophage cell population exert their beneficial
proangiogenic effects mainly by growth factor secretion and
should be more appropriately called circulating angiogenic
cells (CACs), whereas the hematopoietic stem cell–related
populations may yield “late outgrowth EPCs” in culture, also
referred to as “the true EPCs,” enhancing neovasculogenesis
by providing a sufficient number of endothelial cells based on
their high proliferation potency.20–22
The present study was conducted to determine the exact
role of CD34 cells in human neovascularization. Thus far,
most studies on human vasculogenesis were performed with
human cells in small animal models lacking an intact immune
system. We have used a 3-dimensional (3D) in vitro neovas-
cularization model to study the role of human CD34 cells in
vasculogenesis and angiogenesis in a human microvascular
endothelial system under controlled circumstances. This
model provides a tool to dissect the different mechanisms
involved: migration, proliferation, differentiation, stimulation
of, and participation in capillary formation.
Methods
Isolation of Human CD34 Cells
Mononuclear cells (MNCs) were isolated from human umbilical cord
blood (hCB) by density centrifugation (Histopaque 1077). Cells were
washed and CD34 cells were isolated by magnetic bead separation
method (MACS). The residual cells, depleted from CD34 cells,
served as CD34 cell population. The purity of the cell populations
was analyzed by flow cytometry (for detailed description, see
http://atvb.ahajournals.org). Protocols for sampling hCB were ap-
proved by the institutional ethical committee. Written informed
consent was obtained from all mothers before labor and delivery.
Genetic Marking of CD34 Cells
CD34 cells were cultured for 2 days with StemPro-34-SFM
medium containing stem cell factor, flt3 ligand ,and thrombopoietin.
Genetic marking was performed as described previously23 using a
retrovirus encoding the truncated low-affinity nerve growth factor
receptor (LNGFR) as a marker gene. After transduction, CD34 cell
selection was repeated as described to remove cells that had lost
CD34 expression during transduction. Transduction efficiency and
CD34 selection were evaluated by flow cytometry (for detailed
description, see http://atvb.ahajournals.org).
Differentiation and Characterization of EPC/CAC
EPC/CAC were obtained as previously described24 by culturing hCB-
MNC at a density of 2106 cells/cm2 on a gelatin-coated 6-well plate in
M199 medium containing 20% fetal calf serum, penicillin/streptomycin,
endothelial cell growth factor (ECGF), and heparin. At day 7, nonad-
herent cells were removed by thorough washing. Adherent cells were
harvested and used in the 3D neovascularization assay as described.
To confirm endothelial phenotype, a subset of EPC/CAC were
cultured on gelatin-coated coverslips for 7 days, fixed in cold methanol
(20°C), and immunostained for the expression of the endothelial
markers endothelial nitric oxide synthase, vascular endothelial (VE)-
cadherin, kinase insert domain receptor (KDR), CD31, Ulex europeus
agglutinin-I, and the ability to take up acetylated LDL (for detailed
description, see http://atvb.ahajournals.org).
In Vitro Neovascularization Assay
In vitro neovascularization assays were performed in human fibrin
matrices as described previously.25 In short, highly confluent
hMVECs (0.7105 cells/cm2) were seeded in a 1.25:1 split ratio on
fibrin matrices (for detailed description, see http://atvb.ahajournal-
s.org) and cultured in M199 medium supplemented with 10% human
serum, 10% newborn calf serum, penicillin/streptomycin, basic
fibroblast growth factor (bFGF), and tumor necrosis factor- (TNF-
). After 24 hours, the medium was replaced with medium contain-
ing the mediators, with or without different cell populations. Fresh
medium was added every second day. Invading cells and tubular
structures of hMVECs in the 3D fibrin matrix were analyzed by
phase-contrast microscopy. The length and amount of the tube-like
structures was determined using an Olympus-CK2 microscope
equipped with a monochrome charge-coupled device camera (MX5)
connected to a computer with Optimas image analysis software. Six
fixed microscopic fields (7.3 mm2 per field) per well were analyzed
and used to calculate the total length of the tube-like structures,
expressed as mm/cm2.
The Effects of CD34 Cells on In Vitro Capillary
Formation: Homing to Foci of Neovascularization
To compare different cell populations for their migrational behavior
on the angiogenic hMVEC monolayer, cells were added to the
hMVEC culture medium in concentrations of 1% and 10% (ex-
pressed as a percentage of the total number of hMVECs seeded on
the fibrin gel) 24 hours after seeding of the hMVEC. The following
cell populations were studied: CD34 cell–enriched hCB-MNC (1%
CD34, 10% CD34); CD34 cell-depleted hCB-MNC (1% CD34,
10% CD34); and human umbilical vein endothelial cells (HUVECs)
and cells from a lymphoblast cell line (Raji) as proliferating
nonangioblast leukocyte-like cell population.26 The hCB-MNCs
were obtained from 5 donors. All experiments were performed in
duplicate. The cultures were evaluated 7 days after addition of the
cells to the hMVEC culture by 2 independent and blinded observers
using phase-contrast microscopy. Additionally, immunohistochemi-
cal analysis of cross-sections was performed.
The movement of CD34 cells on MVEC monolayers was
recorded by time-lapse video phase contrast microscopy during the
initial 8 hours period (1 frame per 30 seconds). The movement of
individual cells was followed in time. The number of CD34 cells
that reached and those that remained stuck at tubular structures were
counted. The number of cells that entered and remained in randomly
taken comparable areas without capillary tubes were evaluated as
controls.
Blocking antibodies against P-selectin, E-selectin, vascular cell
adhesion molecule, and intercellular adhesion molecule-1 (for details
see http://atvb.ahajournals.org) were added 30 minutes before
CD34 cells and their effects on CD34 cell accumulation at tubular
structures were evaluated after 24 and 72 hours (medium was
renewed after 24 hours).
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Participation in New Capillary Formation
To investigate whether CD34 cells participate in the formation of
new capillary-like tubes, LNGFR-transduced CD34 cells were
used. LNGFR-transduced CD34 cells and nontransduced CD34
cells were compared for phenotypic and functional characteristics.
LNGFR-transduced CD34 cells were added to the hMVEC mono-
layer alone and together with CD34 cells. After 7 days, cultures
were terminated and prepared for immunohistochemical analysis.
Stimulation of New Capillary Formation
The effects on 3D capillary-like tube formation were studied for
CD34 cells alone (1% CD34), CD34 cells together with CD34
cells (1% CD34/10% CD34, ie, ratio of 1:10, whereas the
physiological ratio is 0.5:99.5), CD34 cells alone, EPC/CAC (1%),
HUVECs, and Raji cells. The effects of subpopulations of hCB-
MNC on new capillary formation were assessed in 9 independent
experiments (9 hCB donors). All experiments were performed in
duplicate. Cell populations were added to the hMVEC culture
medium 24 hours after seeding of the hMVEC monolayer. Cultures
were evaluated 7 days later. Total tube length was measured as
described and expressed as percentage of tube length formed by
bFGF/TNF-–stimulated hMVECs.
Immunohistochemical Analysis
Fibrin matrices were fixed and embedded in paraffin. Sections
(5 m) were stained for LNGFR to identify labeled CD34 cells and
were analyzed by light microscopy. The number of LNGFR cells
containing a nucleus was counted and averaged over 5 cross-sections
by a blinded observer and expressed as a percentage of the total
amount of nucleus-containing cells in the monolayer.
To study proliferation of LNGFR cells in situ, consecutive
sections were stained for LNGFR or Ki67 (expressed on all prolif-
erating cells during late G1, S, G2, and M phases of the cell cycle27)
(for detailed description, see http://atvb.ahajournals.org).
Immunofluorescence Double-Staining
Immunofluorescence double-staining for LNGFR and CD31 or Ulex
europeus lectin was performed to confirm the endothelial phenotype
of LNGFR, CD34 cell-derived cells in newly formed capillaries
(for detailed description, see http://atvb.ahajournals.org).
Interaction Between CD34 and CD34 Cells
To investigate the interaction between CD34 and CD34- cells, we
performed several differentiation experiments. Differentiation cul-
tures to obtain EPC/CAC were performed as described. CD34 cells
were cultured in the presence or absence of CD34 cells (ratio 1:100)
Subsequently, cultures were performed in which CD34 and CD34
cells were separated by a 0.4-m pore trans-well system allowing
diffusion of soluble factors without physical contact between CD34
and CD34, cells. Differentiation was expressed as total number of
attached cells per mm2 or as number of attached cells relative to the
number of cultured cells.
Statistical Analysis
The data are expressed as mean  standard error of mean (SEM)
unless otherwise specified. Because of variations in basal tube
formation between different batches of hMVECs, stimulation of
capillary-like tube formation is expressed as percentage of tube
length formed by bFGF/TNF-stimulated hMVECs (ie, versus
“control” culture). To determine whether the different cell popula-
tions (CD34, CD34, CD34/ derived from the same 9 donors or
EPCs derived from 4 different donors) stimulated capillary-like tube
formation significantly as compared with the reference value of
100%, 1-sample t tests with Bonferroni correction were performed.
To compare the growth stimulating effects of CD34 and CD34/
cells, which were all derived from the same 9 donors, a paired t test
was performed. To compare the growth-stimulating effect between
CD34 or CD34/ cells and EPCs that are derived from 4 different
donors, separate independent sample t tests with Bonferroni correc-
tion were used. P0.05 was considered statistically significant.
Results
Isolation and Selection of CD34 Cells
Flow cytometry demonstrated that in the cell population that
was enriched for CD34 cells, 90.11.8% of cells were
CD34. The CD34 cell population was largely depleted
from CD34 cells (99.80.1% CD34 cells).
Characterization of EPC/CAC
Adherent EPC/CAC after 7 days of culture were character-
ized by immunohistochemistry. More than 90% of cells
displayed a spindle-shaped morphology and stained positive
for endothelial nitric oxide synthase, VE-cadherin, VEGFR2
(KDR), CD31, Ulex europeus lectin, and DiI- acetylated LDL
uptake. All controls were negative. In long-term cultures (6
weeks), clusters and confluent monolayers of cobblestone-
like cells were formed (for detailed description, see
http://atvb.ahajournals.org).
CD34 Cells Home to Foci of Neovascularization
hMVECs seeded on top of a fibrin matrix and cultured
without addition of growth factors or cytokines remained as a
quiescent monolayer on top of the matrix. When the hMVECs
were exposed to both bFGF and TNF-, they invaded the
underlying fibrin matrix and formed capillary-like tubular
structures (Figure 1A and 1C). When CD34 cell–enriched
hCB-MNC were added to the hMVEC culture medium,
formation of cell clusters was observed, specifically located
at the sites of new capillary-like tube formation (Figure 1G
and 1H). Addition of higher concentrations of CD34 cells
resulted in larger cell clusters (Figure 1B versus 1D and 1E).
In contrast, no such clusters were seen in the cultures to
which CD34 cells or HUVECs were added (data not shown).
In the cultures to which cells from the Raji lymphoblast cell
line were added, there was a large number of cells and cell
clusters present already at day 2 (Figure 1F). However, they
did not colocalize with newly formed capillary-like structures
but were randomly scattered throughout the culture. Time-
lapse video image microscopy during the first 8-hour
period revealed that the CD34 cells moved randomly over
the endothelial monolayer and remained stuck at the
vascular structures once they reached them (Table). No
accumulation was seen in randomly chosen control fields
of the monolayers. Viability of the homing cells was
confirmed using a calcein uptake assay. Addition of
antibodies against P- and E-selectin, vascular cell adhesion
molecule, and intercellular adhesion molecule-1, either
alone or simultaneously, did not reduce the accumulation
of CD34 cells at the vascular structures (tested with 3
CD34 populations from different donors; for detailed
description, see http://atvb.ahajournals.org).
CD34 Cells Participate in New
Capillary Formation
To study the contribution of CD34 cells to new capillary-
like tube formation, CD34 cells were retrovirally transduced
with the marker gene LNGFR. The CD34 cell population
that underwent genetic marking with the LNGFR gene
contained 922.6% CD34 cells, which is similar to the
nontransduced CD34 cell–enriched mononuclear fraction.
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Transduction efficiency with the LNGFR gene was
39.32.9%. After retroviral transduction with the LNGFR
gene, CD34 cells maintained their phenotypic and functional
characteristics. Addition of transduced CD34 cells to hMVEC
monolayers caused similar homing of cells to angiogenic sites
as observed after addition of nontransduced CD34 cells.
Addition of transduced CD34 cells to hMVEC monolayers
also caused a stimulatory effect on bFGF/TNF-–induced
new capillary-like tube formation that was similar to the
effect observed after addition of nontransduced CD34 cells
(data not shown). Immunohistochemical staining of cross-
sections confirmed homing of LNGFR cells in and around
new capillary sprouts and showed that LNGFR gene–marked
cells participated in new capillary-like structures (Figure 2A).
The transduced cells were fully integrated in the angiogenic
endothelium and stained positive for the endothelial markers
CD31 and Ulex europeus lectin (Figure 2B to 2G). In several
sections, LNGFR cells were observed deep in the tubular
structures, suggesting a pioneering role of CD34 cells
(Figure 2A and 2F). Double-staining with proliferation
marker Ki67 showed that 25% to 40% of the LNGFR cells
were proliferating (Figure 2H and 2I). All controls were
negative.
Quantification of LNGFR cell participation in capillary
formation suggested that addition of CD34 cells (1%) to the
hMVEC monolayer led to a contribution of CD34 cells of
1.00.5% to the new vascular structures. This implies a
significant incorporation of CD34 cells in the endothelial
lining, which was estimated10% of the added CD34 cells.
The exact percentage of participation is difficult to estimate
because CD34 cells proliferated during the 7 days of
incubation.
It should be noted that the transduction efficiency of almost
40% causes a 2.5-fold underestimation of the total amount of
participating CD34 cells.
CD34 Cells Stimulate Neovascularization, Which
Is Further Enhanced by Coculture With
CD34 Cells
Figure 3 shows the effect of different hCB-MNC subpopula-
tions on capillary formation in the 3D fibrin matrix. Addition
of 1% EPC/CAC to the hMVEC-monolayer caused a
6012% increase in capillary formation (P0.05 versus
controls). Overall, if CD34 cells alone (90% purity) were
added to the hMVEC monolayer, only a slight increase in
new capillary-like tube formation was observed (175%
increase compared with controls; P0.05). When CD34
cells were added in combination with CD34 cells, a consid-
erable increase of total tube length was found, which was
similar to the effect of cultured EPC/CAC (6815%;
P0.05). Overall, CD34 cells alone did not cause a signif-
icant increase in tube length (Figure 3A). However, 2 types of
responses could be distinguished in the responding cells. In
preparations of 6 different donors CD34 cells alone did
not significantly increase tube length. In these prepara-
tions, stimulation of growth of vascular structures was only
CD34 Cells Accumulate Specifically on Endothelial
Tubular Structures
Experiment
1
Experiment
2
Cell Accumulation
(% of Cells Entering
the Area)
Tubular structures 13/16 27/34 801%
Nonstructure monolayer
(sum of 3 control areas)
3/56 5/130 4.61.2%
Quantification of the accumulation of CD34 cells was made by time-lapse
video microscopy. CD34 cells (104 cells per cm2) were added to monolayers
of hMVECs that had been induced to generate tubular structures by incubation
with bFGF and TNF-. The movement of individual CD34 cells over the
endothelial monolayer was monitored between 2 and 8 hours after addition of
the cells. To that end, 5 tubular structures in a field were encircled and the
number of CD34 cells that entered and left the marked areas were monitored.
As controls, the surface areas of the 5 structures were projected in 3 directions
to only monolayer areas without tubules or sprouting in the same microscopic
field. The cell numbers of the 3 sets of control data were highly comparable
and their sum is given for both experiments. Cell accumulation is given as the
meanrange.
Figure 1. HMVECs were seeded at confluent density on top of a
3D fibrin matrix and stimulated with bFGF (5 ng/mL) and TNF-
(4 ng/mL). A,B,D,E, Nonphase contrast photmicrographs after
7-day culture without (A) or with 1% CD34 cells (B) or 10%
CD34 cells (D,E), which were added 24 hours after seeding the
hMVECs. A, The arrows indicate sites of capillary-like tube for-
mation by hMVEC. C, Cross-section of tubular structures at
higher magnification. B,D,E, When 1% (B) or 10% CD34 cells
(D,E) were added to the hMVEC monolayer, clusters of CD34
cells accumulated at sites of capillary-like tube formation. G,
Cluster formation at angiogenic sites was visible after 4 days of
culture after addition of 10% CD34 cells (2 larger magnifica-
tion). H, Early accumulated CD34 cells at higher magnification.
Addition of 1% or 10% CD34 cells or 1% or 10% HUVECs did
not cause such cell clustering. F, Addition Raji cells (10%) led
rapidly to increased amounts of cells and cell clusters, which
were randomly scattered throughout the culture without prefer-
ence for tubular structures. Nonphase photomicrographs were
taken after 7 days of culture except for (G) and (H) (phase con-
trast), which were taken at days 4 and 3, and (F), which was
taken at day 2 because of the extensive cell proliferation and
overgrowth. A–E, Data are representative photographs of 6
independent experiments using CD34 cells from different
donors. Similar results were obtained when tubular structures
were induced by addition of VEGF (20 ng/mL) and TNF-
(4 ng/mL). A,B,D–F, Same magnification.
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observed when CD34 and CD34 cells were added
together, whereas none of the separate preparations in-
duced a significant response (Figure 3B). In the prepara-
tions of 3 other donors, the CD34 cells were able to
increase the extent of endothelial tube formation by
themselves, which could not be further enhanced by the
presence of CD34 cells (Figure 3C). The latter finding
suggests that in certain circumstances, for example, when
CD34 cells are in an activated state, CD34 cells may
have a predominant effect on the observed tube length
Figure 2. Histological sections showing hom-
ing, participation, and differentiation of LNGFR
gene–marked CD34 cells in the capillary-like
tubular structures in a fibrin matrix (400).
LNGFR gene–marked cells (LNGFR stained
brown) home to sites of capillary formation,
incorporate, become fully integrated in the en-
dothelial cell monolayer, and acquire a pheno-
type that is morphologically similar to endothe-
lial cells (A). LNGFR gene–marked cells can
also be found deeper in the tubular structures
in direct contact with the matrix (A, arrow). The
small window within (A) gives a schematic
overview. Immunofluorescent double-staining
for LNGFR (green) (B) and Ulex europeus lectin
(red) (C) strongly suggests that incorporated
CD34 cells differentiate into endothelial cells
(yellow) (D). Homing cells before incorporation
do not stain positive for the endothelial cell
marker (arrow) (E). Some of the cells at the tip
of the vascular in-growth are negative for the
endothelial cell marker, suggesting a higher
angiogenic capacity of EPC in an earlier phase
(F). Immunofluorescent double-staining for
LNGFR (green) and CD31 (red) also implies en-
dothelial differentiation of LNGFR gene–marked
CD34 cells (yellow) (G). Histological analysis of
consecutive cross-sections of capillary-like
tubular structures shows the presence of prolif-
erating LNGFR gene–marked cells. H, LNGFR
staining (brown). I, Corresponding consecutive cross-section, stained for Ki-67 nuclear antigen, expressed on proliferating cells (dark
nuclear staining). The open arrows indicate LNGFR-Ki67 double-positive cells, indicating the presence of proliferating CD34 cell–de-
rived cells.
Figure 3. Effects of different subpopulations of
hCB-MNC on capillary-like tube formation. The
left part of (A) shows the effects of different
subpopulations of hCB-MNC on capillary-like
tube formation expressed as a percentage of
tube length formed by bFGF/TNF-–stimulated
hMVEC. The nonphase photomicrographs show
representative examples of the observed tube
formation in the hMVEC monolayer in the pres-
ence of the respective hCB-MNC subpopula-
tions. CD34 cells were added to the hMVEC
culture medium in a concentration of 1% either
alone () or in combination with 10% CD34
cells (/) and compared with control cultures
(bFGF/TNF-–stimulated hMVEC without addi-
tion of cell populations). Data are expressed as
meanSEM of 9 independent experiments (9
hCB donors). The right part of (A) shows the
effects of hCB-derived cultured EPCs/CACs
(EPCs) on tube formation under the same con-
ditions as the left panel and represent the
meanSEM of 4 independent experiments. NS
indicates nonsignificant. *Significant increase
compared with controls (P0.05). **Significant
increase compared with 1% CD34 stimulation
(P0.05). B and C, Effects of the 2 subpopula-
tions of the hCB-MNC given in (A) on capillary-
like tube formation, namely those in which there
was no significant influence on tube formation
by the sole addition of the CD34 cells (B; n6)
and the subset of the 3 CD34 cell prepara-
tions that were able to increase the extent of
endothelial tube formation themselves.
Rookmaaker et al CD34 Cells in Human Neovascularization 1847
enhancement. Neither HUVEC nor cells from the Raji cell
line significantly influenced total tube length.
Interaction Between CD34 and CD34 Cells
When isolated CD34 cells were cultured alone, no differen-
tiation into EPC occurred (00%). However, coculturing of
CD34 cells with CD34 cells resulted in a significant
increase in EPC differentiation (12211/mm2, P0.000
versus CD34 cells alone). To assess whether this increase in
differentiation rate was induced by soluble growth factors,
CD34 cells were cultured separated from CD34 cells by a
membrane that allowed soluble molecules to diffuse freely
but prohibited physical contact between CD34 and CD34
cells. EPC differentiation from CD34 cells in these cultures
was rarely observed (61/mm2, P1.0 versus CD34 cells
alone). Subsequently, experiments were performed in which
CD34 cells were labeled with PKH-26. Previous experi-
ments showed that with this labeling method under these
specific culturing conditions for a period of 7 days minimal
dye transfer (0.1%) occurred. We observed that coculturing
of CD34 and CD34 cells led to a significant increase in
differentiation of CD34 cells to EPC as compared with
cultures in which CD34 cells were cultured alone or cultures
in which CD34 and CD34 cells were separated using a
transwell system (729% versus 0% or 1.50.3%; P0.05).
These experiments suggest that cell–cell contact between
CD34 and CD34 cells is necessary for endothelial differ-
entiation of CD34 cells.
Discussion
In the present study, we used a recently developed in vitro 3D
model to study different aspects of human adult vasculogen-
esis under controlled circumstances and demonstrate that
human CD34 cells selectively home to sites of angiogenic
microvascular human endothelium, proliferate, become fully
integrated in the microvascular endothelial monolayer, are
able to differentiate into endothelial cells in situ, and have a
mild but significant stimulatory effect on new capillary
formation. Interestingly, if CD34 cells are cultured on an
hMVEC monolayer in the presence of CD34 cells this
results in marked enhancement of neovascularization similar
to the effect of cultured EPC/CAC.
Although evidence is accumulating that vasculogenesis
occurs in human postnatal life,1,11,28–30 the origin of the EPC
is still under dispute. Previous studies suggested CD34 cells
as main source of EPC but were criticized because of
CD34-enriched cell populations of low purity and the
possibility of vital dye transfer among cells. Our experiments,
using CD34 cells of high purity (90%) and a very stable
cell labeling method, ie, retroviral transduction with the
marker gene LNGFR, which results in permanent insertion of
the LNGFR gene in the cells, strongly support a role for
CD34 cells as a source of EPC. Moreover, our data indicate
that retroviral vectors can effectively transduce CD34 cells
and that transduction with a marker gene does not influence
their phenotype, homing, or angiogenic capacity. Together
with the ability of purified CD34 cells to selectively home to
angiogenic endothelium and incorporate in the endothelial
monolayer, this suggests that CD34 cells hold promise for
gene therapy applications.
Although in our study administration of a purified popu-
lation of CD34 cells caused relatively modest integration of
these cells in the hMVEC monolayer and only a mild
stimulatory effect on neovascularization, it strongly suggests
homing and incorporation of human CD34 cells in human
microvascular endothelium. Thus far, integration of BM cells
into the endothelium has been mainly assessed in animal
models. Highly variable incorporation rates have been re-
ported, probably because of differences between models in
intensity of endothelial injury. Generally, the number of
incorporated endothelial cells is quite low.31 Thus far, a few
animal studies have assessed the effects of injection human
CD34 cells on neovascularization and incorporation in
animal endothelium. Asahara et al were the first to report
integration of DiI-labeled CD34 cells in 13% or 10% of
capillaries in mouse or rabbit hindlimb ischemia.1 Kocher
reported incorporation of human CD34 cells in 20% to 25%
of total myocardial capillary vasculature in a mouse myocar-
dial infarction model and considerable stimulation of neovas-
cularization resulting in improvement of cardiac function.13
In contrast, Schatteman et al demonstrated that human CD34
cells incorporated and differentiated into endothelial cells
(not quantified) but did not influence restoration of blood
flow in nondiabetic mice with hindlimb ischemia.14 In the
latter experiments, administration of CD34 cells did cause a
marked acceleration of flow restoration in diabetic nude mice,
suggesting that the effects of injected CD34 cells on
neovascularization may depend on (dys)function of the resi-
dent population of endothelial cells and/or angioblasts. In our
model, we used a normal hMVEC population, which may
already have had an optimal capillary-forming capacity. We
cannot exclude the possibility that in the presence of resident
endothelial cell dysfunction administration of CD34 cells
alone may be more effective. However, this cannot fully
explain the modest stimulatory effect of CD34 cells on
neovascularization, as cultured EPC/CAC, administered in
similar concentrations as CD34 cells, did markedly enhance
neovascularization in our model.
An alternative explanation for the limited effect of purified
CD34 cells in our in vitro model as compared with animal
models might be the absence of (endogenous) supporting
cells. Emerging evidence suggests that subsets of hematopoi-
etic cells support capillary growth. Hematopoietic cells have
been shown to release angiogenic factors such as VEGF,
angiopoietins, and MMPs. Additionally, subsets of recruited
hematopoietic cells, particularly myelomonocytic cells, were
shown to support EPC-mediated neovascularization.32 Re-
cently, several in vitro studies have suggested that locore-
gional interactions between CD34 and CD34 cells may be
important for proliferation and differentiation of CD34 cells
into endothelial cells.1,24,33 Interestingly, in our model hom-
ing or incorporation of CD34 cells into the endothelial layer
did not depend on the presence of CD34 cells, suggesting
that angiogenic endothelium may not only express or secrete
factors to recruit CD34 cells but also for their incorporation
and proliferation. However, our data show that although
separate administration of selected CD34 or CD34 cells for
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the majority of the donors had only limited effects on
neovascularization, coincubation of both cell populations
resulted in a consistent and marked increase (68%) in
neovascularization, indicating that interactions between
CD34 cells and CD34 cells can contribute to stimulation of
capillary growth. Our observations that coculturing of CD34
cells with CD34 cells significantly enhances EPC differen-
tiation in vitro, suggest that this is at least partly caused by
enhanced differentiation and incorporation of CD34 cells.
Apart from (CD34 cell–stimulated) CD34 cell incorpo-
ration, enhanced capillary growth after CD34/ cell coincu-
bation may be explained by a stimulatory effect of CD34
cells on endothelial differentiation of CD34 cells. Several
studies have demonstrated that CD34 cells may differentiate
into endothelial cells in vitro.18,20,34 CD34 cells may even be
the main source of cultured EPCs.21 Several studies reported
only rare incorporation of CD34 cells into new capillaries in
vivo1,14 without functional improvements in blood flow. It
has been suggested that CD34 and CD14 cells yield the
“early EPC,” which have no significant proliferative capacity
and contribute to neovascularization mainly by secreting
angiogenic cytokines.20,22 However, Harraz et al15 demon-
strated that CD34 cells and CD34/CD14 cells may incor-
porate into the neovasculature in vivo when coadministered
with CD34 cells. Such potential integration of CD34 cells
is intriguing and warrants further study. However, our study
was not designed to demonstrate or exclude endothelial
differentiation or incorporation of CD34 cells. The aim of
our present study was to investigate specifically the role of
human CD34 cells in human neovascularization. We chose
to use retroviral transduction with a marker gene in our
CD34 cells because this is a very stable and reliable labeling
method and because retrovirally transduced autologous
CD34 cells have already been applied for clinical use. This
labeling method is, however, not suitable for labeling of the
CD34 cell population.
It should be noted that our study is confined to the
formation of human capillary-like tubular structures in vitro.
However, if confirmed, our findings have important clinical
and therapeutic consequences. They suggest that administra-
tion of a CD34-enriched cell population may lead to a
significant improvement of neovascularization, which is sim-
ilar to the effects observed with cultured EPC/CAC. The use
of CD34-enriched cells has the advantage that fresh admin-
istration of these cells after brief manipulation is much easier
than culturing EPCs, which involves prolonged sterile ma-
nipulation. Furthermore, if cultured EPCs/CACs are indeed
monocytes/macrophages, potentially harmful effects caused
by their proinflammatory characteristics have to be taken into
account. Finally, much experience has been obtained over the
years as CD34 cell–enriched cell populations have been
used extensively for treatment of hematologic and nonhema-
tologic malignancies and ex vivo expansion methods have
been developed.23,35,36 Our observation that human CD34
cells selectively home and incorporate in angiogenic endo-
thelium suggests their potential for gene therapy. At last, our
observations suggest an important supportive role for the
CD34 cell population. Further studies should be aimed at
unraveling the interactions between CD34 and CD34 cells.
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